Alnylam Pharmaceuticalsvs.Neurocrine Biosciences
ALNY vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 2.1× larger than Neurocrine Biosciences by market cap; Neurocrine Biosciences trades at the lower P/E (20.5 vs 37.2); year to date, Neurocrine Biosciences leads (−0.4% vs −43.5%).
Side by side
| ALNY | NBIX | |
|---|---|---|
| Market cap | $30B | $14.4B |
| Price | $232.68 | $142.44 |
| Today | +3.6% | +0.8% |
| Return YTD | −43.5% | −0.4% |
| Return 1Y | −50.2% | +1.6% |
| Since June 26, 2026 | −20.1% | −15.5% |
| P/E | 37.2 | 20.5 |
| P/S | 6.3 | 4.3 |
| P/B | 22.2 | 3.9 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More ALNY & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.